October 23, 2019 9:04am

BioMarin Pharmaceuticals (BMRN – last night’s close -$0.69 to $67.73) earnings hits the street today

Quarterly earnings: add two (2) more dates – Alnylam Pharmaceuticals (ALNY) 10/31 and AxoGen (AXGN) 11/6

My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future



When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started …


Dow futures are DOWN -0.01% (-2 points), S&P futures are DOWN -0.06% (-2 points) and NASDAQ futures are UP +0.07% (+6 points)


U.S. stock futures were slightly lower on Wednesday as investors begin the descent of cell and gene therapy earnings season …

European stocks traded mixed after British lawmakers forced Prime Minister Boris Johnson to pause the progression of his Brexit deal while the pan-European Stoxx 600 pared early losses to trade just -0.1% down by mid-morning,

Asia Pacific markets mostly fell in the afternoon; the sterling was hit by Brexit developments. U.K. lawmakers voted to reject a limited time frame for reviewing legislation related to Britain’s withdrawal from the European Union.


Data docket: the Federal Housing Finance Agency will release its house price index for August at 9 a.m.



Estimates, forecasts, LPS (loss-per-share) – big factors, yet to me … is operational spending after previous quarterly results as well as their accomplishment!

The “shorts” will be riding the waves!


Tuesday night’s newsletter heading: “downward motion follows yesterday’s upswing while low volume moves continue expressing descending sentiment. Q3 reporting cycle is off to a run-of-the-mill twitch, though estimates for the period moved south ahead of the earnings season; the actual results to date have been better relative to lowered estimates.”

  • The NASDAQ closed DOWN -58.69 points (-0.72%);
  • The IBB closed up +1.72% and the XBI closed up +0.65%;
  • The close was negative with an A/D line of 16/23, 3 flats, 1 reversed merged (HSGX) and 2 acquired;
  • The range of the 16 upside was +0.29% (CLLS) to +6.17% (SLDB) while the 23 downside ranged from -0.08% (MDXG) to -5.97% (AXGN);
  • 2 out of the 16 upside had higher than the 3 month average volume;
  • 8 out of the 23 downside had higher than the 3 month average volume;


  • October registered 7 positive, 1 neutral and 9 negative close, so far …
  • September, there were 1 holiday, 11 negative, 7 positive and 2 non reported sessions;


Companies in my headlights – It’s your decision; I provide an idea and context:

*** I haven’t changed …  follow the trading herd but … mindful of upcoming quarterly results  and their effect upon share pricing … BUY and get trampled in the coming sessions or SELL into strength or just HOLD and wait to resolve relieve the anxiety until value returns.



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.